Effect of Resveratrol on Treatment of Bleomycin-Induced Pulmonary Fibrosis in Rats

Abstract

Resveratrol has a preventive potential on bleomycin-induced pulmonary fibrosis in prophylactic use; however, it was not studied in the treatment of the fibrosis. This study investigated the role of resveratrol on the treatment of bleomycin-induced pulmonary fibrosis. Intratracheal bleomycin (2.5 mg/kg) was given in fibrosis groups and saline in controls. First dose of resveratrol was given 14 days after bleomycin and continued until sacrifice. On 29th day, fibrosis in lung was estimated by Aschoft's criteria and hydroxyproline content. Bleomycine increased the fibrosis score (3.70 ± 1.04) and hydroxyproline levels (4.99 ± 0.90 mg/g tissue) as compared to control rats (1.02 ± 0.61 and 1.88 ± 0.59 mg/g), respectively. These were reduced to 3.16 ± 1.58 (P = 0.0001) and 3.08 ± 0.73 (P > 0.05), respectively, by resveratrol. Tissue malondialdehyde levels in the bleomycin-treated rats were higher (0.55 ± 0.22 nmol/mg protein) than that of control rats (0.16 ± 0.07; P = 0.0001) and this was reduced to 0.16 ± 0.06 by resveratrol (P = 0.0001). Tissue total antioxidant capacity is reduced (0.027 ± 0.01) by bleomycine administration when compared control rats (0.055 ± 0.012 mmol Trolox Equiv/mg protein; P = 0.0001) and increased to 0.041 ± 0.008 (P = 0.001) by resveratrol. We concluded that resveratrol has some promising potential on the treatment of bleomycin-induced pulmonary fibrosis in rats. However, different doses of the drug should be further studied.

Resveratrol inhibits rat pulmonary fibroblast proliferation through modulation of TLR4/NF-B pathway

“…seldom known (Akgedik et al, 2012). In the present study, resveratrol treatment downregulated plasma level of inflammatory factors in vivo.…”

“…Previous study has demonstrated that resveratrol, as a antioxidant, does not only decrease reactive oxygen species (ROS) but also show an anti-inflammatory effect (Bradamante et al, 2004). Recent research suggested that resveratrol treat-ment led to inhibit PF in bleomycin (BLM)-induced PF, while the underlying mechanism remains unknown (Akgedik et al, 2012). So the present study is designed to investigate whether the anti-inflammatory effect of resveratrol is involved in its therapeutic effect of PF.…”

Blocking Sirtuin 1 and 2 Inhibits Renal Interstitial Fibroblast Activation and Attenuates Renal Interstitial Fibrosis in Obstructive Nephropathy

“…Wang et al (2008) reported that most of the class III HDAC activities, including those of SIRT1, were increased in patients with primary myelofibrosis. However, resveratrol, a naturally occurring compound believed to be an activator of SIRT1, prevents fibrosis in a bleomycin-induced lung injury model (Akgedik et al, 2012). Similarly, activation of SIRT1 by resveratrol, or SRT1720 [N-(2-(3-(piperazin-1-ylmethyl)imidazo[2,1-b]thiazol-6-yl)phenyl) quinoxaline-2-carboxamide hydrochloride], also inhibits renal fibrosis (Li et al, 2010).…”

Anti-Fibrotic Potential of Nicorandil in the Treatment of Bleomycin Induced Pulmonary Fibrosis

“…Previous studies demonstrated that anti-oxidant agents ameliorated the accumulation of leukocytes in bronchial lavage fluid and lung tissue which agrees with our findings. [12][13][14][15][16][17][18][19] The pathophysiology of Bleomycin-induced lung injury typically consisted of two overlapping stages; an early inflammatory phase characterized by leukocyte infiltration and injury to alveolar epithelial cells, and a subsequent fibro-proliferative phase with matrix remodeling and fibrosis. 20 Haematoxylin & Eosin (H&E) staining results in BLM control group showed that acute inflammations were prominent with moderate or severe hemorrhage, widened alveolar septa, and infiltration of numerous inflammatory cells predominated by macrophages, neutral granulocytes, and lymphocytes.…”